HMGA2: A Biomarker in Gynecologic Neoplasia.
HMGA2: A Biomarker in Gynecologic Neoplasia.
复制标题
DOI：
10.14218/jctp.2021.00018
复制
发表时间：
2022
期刊：
影响因子：
--
通讯作者：
Wei JJ
中科院分区：
文献类型：
--
作者：
Wei JJ
高迁移率族A2基因(HMGA2)是一种致癌胎儿蛋白，在胎儿发育中正常表达，成年期几乎在所有器官和组织类型中完全关闭。由于染色体易位，它在某些间叶性肿瘤中再次上调或过度表达，在恶性上皮性肿瘤中通过转录调节再次表达。HMGA2的过表达既可以推动肿瘤的发展，也可以促进肿瘤的侵袭性生长。许多妇科肿瘤，包括子宫平滑肌肿瘤和卵巢癌，都与HMGA2的过表达有关。本文就HMGA2及其作为妇科肿瘤生物标志物的表达及其临床应用的研究进展作一综述。
High Mobility Group A2 gene (HMGA2), an oncofetal protein, is normally expressed in fetal development and completely shuts down in almost all organs and tissue types during adulthood. It is upregulated or overexpressed again in certain mesenchymal neoplasms due to chromosomal translocations and in malignant epithelial tumors through transcription regulation. HMGA2 overexpression can either drive tumor development or promote the aggressiveness of tumor growth. Many gynecologic neoplasms, including uterine smooth muscle tumors and ovarian cancer, are associated with HMGA2 overexpression. In this article, we review recent developments in the study of HMGA2 and its expression as a potential biomarker for gynecologic neoplasms and clinic application.